Can-Fite Biopharma Operating Income

As of the most recent data (December 2025), CANF shows a operating income of $-10M. That compares with $-8.1M in the prior-year period — down 22.4% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, CANF's operating income is now $-10M (was $-8.1M) — a 22.4% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Can-Fite Biopharma is outperforming or lagging.

Tracking CANF's operating income over time shows whether Can-Fite Biopharma is scaling, shrinking, or reshaping that part of the business. The current reading is $-10M That compares with $-8.1M in the prior-year period — down 22.4% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this operating income page, Stockcircle has Can-Fite Biopharma's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect operating income (currently $-10M) with ownership activity and broader fundamentals.

Can-Fite Biopharma's operating income is $-10M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.